| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1364168 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
A novel series of hepatitis C virus (HCV) NS3/4A protease inhibitors bearing a P2-P4 macrocycle and a P1-P1′ α-ketoamide serine trap is reported. The NS3 protease, which is essential for viral replication, is considered one of the most attractive targets for developing novel anti-HCV therapies. The optimization of both the macrocycle and the warhead portions led to the discovery of compounds 8b and 8g with a good activity both in the enzyme as well as in the cell based (replicon) assays with favorable PK profile in a preclinical species.
Graphical abstractDesign, synthesis and biological evaluation of a new series of hepatitis C virus (HCV) NS3/4A protease inhibitors bearing a P2-P4 macrocycle and a P1-P1′ α-ketoamide warhead is described.Figure optionsDownload full-size imageDownload as PowerPoint slide
